You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

CLINICAL TRIALS PROFILE FOR MARCAINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Marcaine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00180687 ↗ Clinical Trial of the Use of Intraperitoneal Local Anaesthetic Completed Imperial College London Phase 3 2004-10-01 Patients undergoing keyhole gall bladder removal will be divided into 3 groups, one control, one will have local anaesthetic and the third will have normal saline nebulised into their abdomen before closure of the wounds to reduce postoperative pain. These medications will be given on top of the standard pain management protocol.
NCT00472134 ↗ Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump Completed University Hospitals Cleveland Medical Center N/A 2005-12-01 The purpose of this study is to determine the effects of a local anesthetic dispensed via a tiny catheter device, called the ON-Q PainBuster pump, placed during surgery on top of the mesh used in the laparoscopic repair of ventral hernias. The goals are: - reducing postoperative pain from this procedure - decreasing length of hospital stay - reducing or eliminating amount of post-operative narcotics used
NCT00508066 ↗ Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery Completed Shriners Hospitals for Children Phase 4 2007-05-01 The purpose of this study is to evaluate the effects of continuous local anesthetic delivery on the immediate post-op recovery of patients undergoing spinal fusion surgery for congenital or idiopathic scoliosis.
NCT00508976 ↗ Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic Completed Pinnacle Health System Phase 2 2007-06-01 The purpose of this study is to determine if pre-incisional lidocaine injection, instilled liquid bupivacaine, intra-abdominal aerosolized bupivacaine, or post-operative bupivacaine injection is superior in post-operative pain control in laparoscopic bariatric surgical patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Marcaine

Condition Name

Condition Name for Marcaine
Intervention Trials
Pain, Postoperative 38
Postoperative Pain 26
Pain 26
Anesthesia, Local 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Marcaine
Intervention Trials
Pain, Postoperative 93
Fractures, Bone 9
Hernia, Inguinal 8
Hernia 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Marcaine

Trials by Country

Trials by Country for Marcaine
Location Trials
United States 161
Egypt 38
Turkey 19
Canada 17
Belgium 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Marcaine
Location Trials
California 20
New York 17
Illinois 13
Pennsylvania 10
Ohio 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Marcaine

Clinical Trial Phase

Clinical Trial Phase for Marcaine
Clinical Trial Phase Trials
Phase 4 110
Phase 3 24
Phase 2/Phase 3 4
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Marcaine
Clinical Trial Phase Trials
Completed 139
Recruiting 51
Unknown status 32
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Marcaine

Sponsor Name

Sponsor Name for Marcaine
Sponsor Trials
Istanbul University 12
Cairo University 12
Assiut University 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Marcaine
Sponsor Trials
Other 337
Industry 18
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Marcaine: Clinical Trials, Market Analysis, and Projections

Introduction to Marcaine

Marcaine, also known as bupivacaine, is an amide local anesthetic widely used for producing local or regional anesthesia or analgesia in various medical procedures. It is available in different concentrations and can be used with or without epinephrine. Here, we will delve into the current clinical trials, market analysis, and future projections for Marcaine.

Clinical Trials and Development

Ongoing Research and Trials

While Marcaine itself is an established drug, ongoing research and clinical trials are focused on improving pain management strategies and developing new therapeutic approaches. For instance, the Early Phase Pain Investigation Clinical Network (EPPIC-Net) is working on enhancing pain treatments, including the development of new analgesics and biomarkers, which could indirectly influence the use and efficacy of drugs like Marcaine[1].

Specific Pain Conditions

Although Marcaine is not the primary focus of EPPIC-Net trials, the network's efforts to develop innovative clinical trial paradigms and validate biomarkers for pain outcomes can benefit the broader field of pain management, including the use of local anesthetics like Marcaine.

Market Analysis

Global Local Anesthesia Drugs Market

The global local anesthesia drugs market, which includes Marcaine, is expected to grow significantly. By 2025, this market is projected to reach USD 5.26 billion and is anticipated to grow at a CAGR of 3.40% to reach USD 6.22 billion by 2030. North America currently holds the largest market share, while the Asia-Pacific region is expected to be the fastest-growing market during the forecast period[2].

Bupivacaine Injection Market

Specifically focusing on bupivacaine (Marcaine), the global bupivacaine injection market was valued at USD 1,120.21 million in 2023 and is estimated to reach USD 2,088.37 million by 2032, growing at a CAGR of 5.6% during the forecast period. This growth is driven by factors such as the high prevalence of conditions requiring anesthetic procedures and growing opportunities in anesthetic drug approvals[5].

Market Projections

Growth Drivers

The market for Marcaine and other local anesthetics is driven by several key factors:

  • Increasing Surgical Procedures: The rising number of surgical procedures, including hip replacements, coronary artery bypass surgeries, and spinal surgeries, fuels the demand for local anesthetics like Marcaine[3].
  • Chronic Diseases: The growing burden of chronic diseases that require complex surgical procedures also contributes to the increased demand for these drugs[3].
  • Advancements in Anesthesia: Continuous advancements in anesthesia techniques and the development of new products are expected to further drive market growth.

Regional Market Performance

  • North America: Currently, North America holds the largest market share in the global local anesthesia drugs market, including bupivacaine. This region is expected to continue its dominance due to advanced healthcare infrastructure and high adoption rates of new medical technologies[2][5].
  • Asia-Pacific: This region is anticipated to be the fastest-growing market due to increasing healthcare spending, a large patient population, and improving healthcare infrastructure[2].

Key Players and Competition

The market for local anesthesia drugs, including Marcaine, is competitive with several major players:

  • Pfizer Inc.: As the manufacturer of Marcaine, Pfizer is a significant player in the market.
  • Fresenius SE & Co. KGaA: Another major company operating in the global local anesthesia drugs market.
  • Pacira Pharmaceuticals, Inc.: Known for its focus on non-opioid pain management solutions.
  • Baxter International Inc.: A key player in the healthcare industry, including the market for local anesthetics[2].

Safety and Usage Considerations

Clinical Use and Limitations

Marcaine is indicated for various surgical and diagnostic procedures but comes with specific limitations and risks. For example, it is crucial to avoid using Marcaine solutions containing antimicrobial preservatives for epidural or caudal anesthesia due to safety concerns. A test dose is often recommended to detect unintended intravascular or intrathecal injection, which can lead to systemic toxic reactions or other serious adverse effects[4].

Monitoring and Precautions

Healthcare providers must closely monitor patients for early clinical signs of toxicity following each test dose and full dose administration. Signs of methemoglobinemia, a potential side effect, require immediate treatment to prevent severe CNS and cardiovascular adverse effects[4].

Key Takeaways

  • Market Growth: The global local anesthesia drugs market, including bupivacaine (Marcaine), is expected to grow significantly, driven by increasing surgical procedures and the burden of chronic diseases.
  • Regional Performance: North America dominates the market, while the Asia-Pacific region is the fastest-growing.
  • Clinical Trials: Ongoing research in pain management can indirectly benefit the use and efficacy of Marcaine.
  • Safety Considerations: Healthcare providers must be cautious of potential side effects and follow recommended dosages and monitoring protocols.

FAQs

What is the projected market size for the global local anesthesia drugs market by 2030?

The global local anesthesia drugs market is expected to reach USD 6.22 billion by 2030, growing at a CAGR of 3.40% from 2025 to 2030[2].

Which region is the fastest-growing market for local anesthesia drugs?

The Asia-Pacific region is estimated to grow at the highest CAGR over the forecast period (2025-2030)[2].

What is the estimated market size for the global bupivacaine injection market by 2032?

The global bupivacaine injection market is estimated to reach USD 2,088.37 million by 2032, growing at a CAGR of 5.6% during the forecast period[5].

What are the key drivers for the growth of the bupivacaine injection market?

The growth is driven by factors such as the high prevalence of conditions requiring anesthetic procedures and growing opportunities in anesthetic drug approvals[5].

What are the potential risks associated with the use of Marcaine?

Potential risks include systemic toxic reactions, high spinal or cardiovascular effects from unintended intravascular or intrathecal injection, and methemoglobinemia[4].

Sources

  1. Early Phase Pain Investigation Clinical Network (EPPIC-Net) - Heal.nih.gov
  2. Local Anesthesia Drugs Market - Size, Share & Industry Trends - Mordorintelligence.com
  3. US Intrathecal Drugs for Post Operative Pain Management Market - Fortunebusinessinsights.com
  4. MARCAINE AND EPINEPHRINE - VIAL - Pfizermedicalinformation.com
  5. Bupivacaine Injection Market Size, Share & Trends Analysis Report - Straitsresearch.com

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.